The Medical Letter on Drugs and Therapeutics
Transdermal Rotigotine (Neupro) for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Rotigotine (Neupro – Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson’s disease (PD).

DOPAMINE AGONISTS — Dopamine agonists such as ropinirole (Requip) and pramipexole (Mirapex) are often used for initial treatment of PD but must be taken 3 times each day.1 Pergolide (Permax, and others), an ergot-derived dopamine agonist used for many years, has recently been removed from the market due to an increased risk of cardiac valve regurgitation.2,3 Bromocriptine (Parlodel, and others), another ergotderived dopamine agonist, is still available, but is not commonly used for PD.

CONTINUOUS VS. PULSATILE — Oral dopamine agonists are dosed several times a day, possibly causing pulsatile dopamine ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Transdermal Rotigotine (Neupro) for Parkinson's Disease
Article code: 1268a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian